Data as of May 17
| +0.03 / +1.99%|
The 3 analysts offering 12-month price forecasts for Peregrine Pharmaceuticals Inc have a median target of 3.00, with a high estimate of 4.00 and a low estimate of 2.50. The median estimate represents a +94.81% increase from the last price of 1.54.
The current consensus among 3 polled investment analysts is to Buy stock in Peregrine Pharmaceuticals Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.